Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ.
Tenney DJ, et al. Among authors: warner n.
Antimicrob Agents Chemother. 2004 Sep;48(9):3498-507. doi: 10.1128/AAC.48.9.3498-3507.2004.
Antimicrob Agents Chemother. 2004.
PMID: 15328117
Free PMC article.